Objective To assess evidence of overall survival (OS) benefits of cancer drugs listed in China’s National Reimbursement Drug List (NRDL), the guiding standard for public insurance coverage of drugs ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback